pioglitazone has been researched along with Heart Defects, Congenital in 2 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Heart Defects, Congenital: Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| García-Beltran, C | 1 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Malpique, R | 1 |
| López-Bermejo, A | 1 |
| de Zegher, F | 1 |
| Ibáñez, L | 1 |
| Villarroya, F | 1 |
| Liu, Y | 1 |
| Luo, Q | 1 |
| Su, Z | 1 |
| Xing, J | 1 |
| Wu, J | 1 |
| Xiang, L | 1 |
| Huang, Y | 1 |
| Pan, H | 1 |
| Wu, X | 1 |
| Zhang, X | 1 |
| Li, J | 1 |
| Yan, F | 1 |
| Zhang, H | 1 |
1 trial available for pioglitazone and Heart Defects, Congenital
| Article | Year |
|---|---|
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
1 other study available for pioglitazone and Heart Defects, Congenital
| Article | Year |
|---|---|
Suppression of Myocardial Hypoxia-Inducible Factor-1α Compromises Metabolic Adaptation and Impairs Cardiac Function in Patients With Cyanotic Congenital Heart Disease During Puberty.
Topics: Animals; Disease Models, Animal; Fatty Acids; Glucose; Glycolysis; Heart Defects, Congenital; Humans | 2021 |